Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Propanc Biopharma, Inc.

< Previous 1 2 Next >
CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
Propanc Biopharma Provides Shareholder Update
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
From Propanc Biopharma, Inc.
Via GlobeNewswire
Tickers PPCB
Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Provides Shareholder Update
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Announces Strategic Pharma Partnering Initiative
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCBD
Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCBD
Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Announces Reverse Stock Split
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.